Should You Buy Danaher Corp (DHR) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now. Despite solid long-term fundamentals and broadly positive Wall Street targets, the post-earnings selloff is occurring within a weakening technical trend (bearish momentum and broken support), and pattern-based odds point to further downside over the next month. For a beginner long-term investor who is impatient and doesn’t want to wait for a cleaner setup, I would hold off buying today rather than chase this dip.
Technical Analysis
Price/Trend: DHR fell sharply in the regular session (-4.76%) and is ~225 post-market, which is below the key Pivot (234.04) and below/around S1 (226.51), pressing toward S2 (221.86). This suggests the stock has broken an important support zone and is still in a short-term downtrend.
Momentum: MACD histogram is negative (-1.319) and expanding lower, which typically signals increasing bearish momentum.
RSI: RSI_6 is ~25.35, which indicates the stock is short-term oversold (bounce risk exists), but oversold alone is not a buy signal when MACD is still deteriorating.
Moving averages: Converging moving averages implies no strong base has formed yet; the recent breakdown increases the odds that rallies get sold.
Near-term levels: Resistance is now the prior support area near 226.5–234 (S1/Pivot). A more constructive entry would be after stabilization above that zone; otherwise the next area to watch is ~221.9 (S2).
Analyst Ratings and Price Target Trends
Recent trend: Analysts have been raising price targets into early Jan 2026 while maintaining positive ratings (TD Cowen to $270, Guggenheim to $275, BofA to $265, Goldman initiated Buy at $265; Evercore raised to $250 Outperform). One more cautious voice is Wells Fargo at Equal Weight with a $240 target.
Wall Street pros: (1) Expected normalization/recovery in life science/diagnostics tools demand into 2026, (2) Danaher’s quality/scale and leverage to improving end markets, (3) multiple firms see room for upside as headwinds fade.
Wall Street cons: (1) Timing uncertainty in drug discovery recovery and academic/government spending, (2) policy/healthcare reimbursement risks mentioned broadly for the space, (3) with guidance merely in-line, near-term multiple expansion may be harder without clearer acceleration.
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235 USD and a high forecast of 310 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235 USD and a high forecast of 310 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 235.750
Current: 235.750
